Contact immunotherapy is an increasingly used, effective means of treating cutaneous viral warts. Dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester are the most frequently used modalities, showing slight variances in adverse effect profiles and efficacy. All of these agents serve as safe treatment modalities when administered according to the guidelines recommended herein. We review the value of contact immunotherapy in the treatment of cutaneous viral warts.
Get full access to this article
View all access options for this article.
References
1.
AndrophyEJ, KirnbauerR. Human papilloma virus infections. In: GoldsmithLA, et al., eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York, NY: McGraw-Hill; 2012; 2421–2433.
2.
Grussendorf-ConenEI, JacobsS. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr Dermatol, 2002; 19(3): 263–266.
3.
MassingAM, EpsteinWL. Natural history of warts. A two-year study. Arch Dermatol, 1963; 87: 306–310.
4.
SriJC, et al.Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol, 2012; 66:(2): 292–311.
5.
CiconteA, et al.Warts are not merely blemishes on the skin: a study on the morbidity associated with having viral cutaneous warts. Australas J Dermatol, 2003; 44(3): 169–173.
HellerC, et al.Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression. J Biol Chem, 2011; 286(13): 10983–10997.
8.
LeeAN, MallorySB. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol, 1999; 41(4): 595–599.
9.
UpitisJA, KrolA. The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J Cutan Med Surg, 2002; 6(3): 214–217.
10.
ChoiMH, et al.Comparative study on the sustained efficacy of diphencyprone immunotherapy versus cryotherapy in viral warts. Pediatr Dermatol, 2008; 25(3): 398–399.
DunaginWG, MillikanLE. Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalities. J Am Acad Dermatol, 1982; 6(1): 40–45.
13.
PollockB, HighetAS. An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts. J Dermatolog Treat, 2002; 13(2): 47–50.
14.
ModlinRL, et al.Innate and adaptive immunity in the skin. In: GoldsmithLA, et al., eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York, NY: McGraw-Hill; 2012; 104–125.
15.
SilverbergNB, et al.Squaric acid immunotherapy for warts in children. J Am Acad Dermatol, 2000; 42(5 pt 1): 803–808.
16.
Goihman-YahrM. Combined immunotherapy of recalcitrant warts. Int J Dermatol, 2006; 45(5): 627.
17.
MicaliG, et al.Treatment of cutaneous warts with squaric acid dibutylester: a decade of experience. Arch Dermatol, 2000; 136(4): 557–558.
LewisHM. Topical immunotherapy of refractory warts. Cutis, 1973; 12: 863–865.
20.
SandersBB, SmithKW. Dinitrochlorobenzene immunotherapy of human warts. Cutis, 1981; 27(4): 389–392.
21.
Rosando-CancinoMA, et al.Treatment of multiple and stubborn warts in children with 1-choloro-2,4-dinitrobenzene (DNCB) and placebo. Dermatol Rev Mex, 1989; 33: 245–252.
22.
WilsonP. Immunotherapy versus cryotherapy for hand warts: a controlled trial [Abstract]. Scott Med J, 1983; 28: 191.
23.
LeeS, et al.Therapeutic effect of dinitrochlorobenzene (DNCB) on verruca plana and verruca vulgaris. Int J Dermatol, 1984; 23(9): 624–626.
24.
BucknerD, PriceNM. Immunotherapy of verrucae vulgares with dinitrochlorobenzene. Br J Dermatol, 1978; 98(4): 451–455.
25.
RampenFH, SteijlenPM. Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology, 1996; 193(3): 236–238.
26.
ArmourK, OrchardD. Treatment of palmoplantar warts with a diphencyprone and salicylic acid ointment. Australas J Dermatol, 2006; 47(3): 182–185.
27.
IijimaS, OtsukaF. Contact immunotherapy with squaric acid dibutylester for warts [corrected]. Dermatology, 1993; 187(2): 115–118.
BuckleyDA, et al.Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol, 1999; 141(2): 292–296.
30.
KwokCS, HollandR, GibbsS. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol, 2011; 165(2): 233–246.
31.
EriksenK. Treatment of the common wart by induced allergic inflammation. Dermatologica, 1980; 160(3): 161–166.
32.
GraysonRJ, RatnerSW, ShapsRS. Topical DNCB therapy for recalcitrant Verruca plantaris. J Am Podiatry Assoc, 1982; 72(11): 557–559.
33.
VirabenR, LabrousseJL, BazexJ. Erythema multiforme due to DNCB. Contact Dermatitis, 1990; 22(3): 179.
34.
OrecchiaG, et al.Treatment of multiple relapsing warts with diphenciprone. Dermatologica, 1988; 177(4): 225–231.
35.
PerretCM, et al.Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica, 1990; 180(1): 5–7.
36.
PuigL, et al.Erythema multiforme-like reaction following diphencyprone treatment of plane warts. Int J Dermatol, 1994; 33(3): 201–203.
37.
PericinM, TruebRM. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology, 1998; 196(4): 418–421.
KimJK, et al.Erythema multiforme due to diphenylcyclopropenone. Ann Dermatol, 1996; 8(4): 250–252.
40.
VenugopalSS, MurrellDF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol, 2010; 146(5): 475–477.
